It also reviews investigations of factors influencing life span and rates of aging changes, especially interventions expected to hit multiple targets and to affect multiple outcomes, such as dietary and exercise interventions. Proposals are typically clinical-translational efforts (including interventional clinical trials) and involve human subjects.
The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Falls, syncope, frailty, immobility, malnutrition, sarcopenia, loss of functional independence, and failure to thrive.
- Delirium, mild cognitive impairment, and dementia when the emphasis is on the effects of age-related systemic factors such as diminished organ function across multiple systems, multi-organ failure, multi-morbidity, polypharmacy, or multi-faceted sensory and motor changes on cognition.
- Multicomponent, pleiotropic (e.g., exercise, nutrition) and mechanism-driven intervention studies addressing geriatric syndromes or outcomes spanning multiple systems.
- Effects of polypharmacy or multi-morbidities or chronic pain on health status and clinical outcomes in older adults.
- Attempts to increase lifespan including caloric restriction and studies of animal models of human populations especially resistant to aging.
- Treatments to ameliorate age effects on bone or skeletal muscle physiology and function
Shared Interests and Overlaps
Cellular Mechanisms in Aging and Development [CMAD] and ASG have shared interest in many areas. CMAD reviews applications pertaining to fundamental biological questions on mechanisms of aging and the regulate healthspan and lifespan whereas ASG focuses on clinical geroscience and geriatrics. ASG generally reviews human subjects, non-human primates whereas CMAD generally reviews applications using animal models.
There are shared interests with Skeletal Muscle and Exercise Physiology [SMEP] in sarcopenia and skeletal muscle function. Grant applications that focus on mechanisms of sarcopenia, or on skeletal muscle endpoints as consequences of aging sydromes such as multi-morbidity and polypharmacy will generally be reviewed in ASG. Applications to evaluated pleiotropic interventions that include skeletal muscle endpoints (along with multiple others) as outcomes in older adults will generally be assigned to ASG (exercise studies, for example). Grant applications with primary focus on skeletal muscle biology or function in response to sarcopenia and aging, including exercise interventions that focus on muscle, are usually reviewed in SMEP.
There are shared interests with Musculoskeletal Rehabilitation Sciences [MRS] on topics in age-related changes on human mobility and exercise with aging. Grant applications that focus on the motor performance, balance, and mobility as effects of geriatric syndromes, including multi-morbidity and polypharmacy, will generally be reviewed in ASG. Pleiotropic interventions that include mobility and exercise (etc.) as outcomes will generally be assigned to ASG. Applications that focus on rehabilitative interventions aiming to improve motor performance, balance and mobility in elderly people, including mobility support devices will generally be assigned to MRS.
There are shared interests with Clinical and Integrative Cardiovascular Sciences [CICS] on topics related to aging effects on cardiac physiology, modulation of cardiac response, neural control of the cardiovascular system, and treatments of heart disease. Applications that investigate these topics as outcomes or effects of geriatric syndromes, including dementias, failure to thrive, multi-morbidity and polypharmacy, will generally be reviewed in ASG. Pleiotropic interventions that include cardiac endpoints as outcomes (among others) will generally be assigned to ASG. Otherwise, applications on aging effects on these cardiac topics will generally be reviewed in CICS.
There are shared interests with the Cellular and Molecular Immunology -B [CMIB], Hypersensitivity, Autoimmune, and Immune-mediated Diseases [HAI] and Innate Immunity and Inflammation [III] study sections regarding age-related changes in the adaptive and innate immune systems. Grant applications with primary focus of the impact of aging on the mechanistic pathways affecting immune cells and their molecular function are usually reviewed in study sections of the Immunology IRG (IMM) such as CMIB and III or autoimmune diseases in HAI. Applications focused on age-related changes in complex physiology that include an immune component are primarily reviewed in ASG.
There are shared interests with Clinical Neuroscience and Neurodegeneration (CNN) regarding delirium, cognitive impairment, and dementia. ASG generally reviews applications to investigate these topics when the emphasis is on the effects of age related systemic factors such as diminished organ function across multiple systems, multi-organ failure, multi-morbidity, polypharmacy, or multi-faceted sensory and motor changes. CNN generally reviews the application when the focus is on the etiology or pathogenesis of particular dementing illnesses including Alzheimer’s disease, Parkinson’s disease, Frontotemporal lobe dementias, etc.
Both ASG and Neurological, Aging and Musculoskeletal Epidemiology (NAME) review applications focused on age-related conditions. Applications using an epidemiological approach to investigate age-related conditions are generally reviewed in NAME. However, applications that use established epidemiological cohorts to investigate the etiology, pathophysiology, or treatment of geriatric syndromes such as delirium, frailty or sarcopenia are generally reviewed in ASG. Applications proposing to conduct interventional clinical trials of age-related conditions are reviewed in ASG. Secondary data analyses of clinical trials data of aging conditions will generally go to NAME.